Developers can integrate AnySearch into AI Agent workflows to monitor industry news automatically. By combining AnySearch with scheduled tasks, historical records, and event deduplication, developers can build workflows that regularly discover relevant news and organize important updates without maintaining their own crawler infrastructure, search indexes, or multiple data-source integrations.
AnySearch supports API, MCP, and Skills integration, allowing developers to connect its search capabilities to their AI applications and agents. It provides access to public webpages and specialized search domains, helping developers find relevant, up-to-date information across different industries. Individual developers can use the Free or Pro plan to build personal news briefings and automated monitoring workflows based on their needs and API usage.
This article explains how to integrate AnySearch into an AI Agent, design an automated news monitoring workflow.
Case Study: Tracking Antibody–Drug Conjugate (ADC) Developments in China with AnySearch
Pharmaceutical industry monitoring requires identifying companies, drug names, clinical trial phases, and disclosure dates. It also requires distinguishing between different types of developments, such as clinical trial authorizations, Phase III trial registration updates, and marketing approvals. In this example, AnySearch Enterprise was used to search for information related to the following question:
What new developments have there been in China over the past seven days involving ADC drugs entering Phase III clinical trials or receiving approval? List the companies involved, drug names, event dates, and original sources.
Test details: We ran the search on November 17, 2026, Beijing time. The monitoring window covered seven calendar days, from November 11 through the time of the test on November 17.
Search Request Details
This test used AnySearch search capabilities through Skill. It combined general web search with specialized clinical trial searches. Additional searches were then run based on drug names, registration numbers, and company announcements. Extract was used to retrieve the full text of key webpages.
| Metric | Test Results |
|---|---|
| Search Calls | 30, including the original query and 29 additional searches |
| Full-Text Extraction Calls | 8 calls, retrieving full text from clinical trial registry pages, company websites, announcements, and other sources |
| Raw Search Results | 291, including duplicate results across queries |
A total of 39 AnySearch API requests were made, including the search and full-text extraction requests listed above, as well as one capability query. The number of requests does not directly equal the amount of billable quota consumed.
Key Finding: One Phase III Trial Registration Update in China
| Company | Drug Name | Confirmed Development | Date and Details | Original Source |
|---|---|---|---|---|
| Qilu Pharmaceutical Co., Ltd. | QLS5132 for Injection | Registration No. CTR20264260; Phase III clinical trial; status: "Ongoing (Not Yet Recruiting)" | First publicly disclosed on November 13, 2026. The dates of first patient enrollment and first dosing were not provided. | Drug Clinical Trial Registration Page |
Qilu Pharmaceutical's official website was used to confirm that QLS5132 is an ADC. This information was not counted as a new event within the monitoring window.
At the time of the test, one domestic Phase III trial registration update involving an ADC drug was confirmed within the monitoring period. No new marketing approvals for ADC drugs were confirmed during the same period. These findings reflect the information retrieved and verified in this search. They do not mean that no other developments occurred during that period.
Following Industry Leads to Original Sources
This search covered industry reports, company websites, clinical trial registration records, public announcements, and other sources.
| Information Source | Key Information Retrieved | Role in the Task |
|---|---|---|
| Drug Clinical Trial Registration and Information Disclosure Platform | QLS5132's applicant company, registration number, Phase III classification, first public disclosure date, and recruitment status | Provides the original evidence for the domestic Phase III clinical trial registration update |
| Qilu Pharmaceutical Official Website | QLS5132's ADC identity, target, and R&D background | Provides additional information about the drug's identity and development background |
| Hengrui Medicine Announcement Repost and Public Archive of the Original Announcement | Clinical trial authorizations involving SHR-A2102 and SHR-4849, and the Phase Ib/II combination study plan | Helps distinguish clinical trial authorizations, Phase III clinical trial developments, and marketing approvals |
| Takeda Official Website | Announcement and original publication date for IBI343 / TAK-921 receiving SAKIGAKE designation | Identifies recent related developments and their regulatory status |
| Mabwell Official Website and Sichuan Biokin Public Announcements | Original disclosure dates and event details corresponding to related reports | Determines whether recently circulated reports correspond to new developments within the monitoring window |
Information Filtering: Removing Duplicate Links and Separating Past Events from Related Leads
Multiple searches can retrieve information from different sources. However, monitoring results should be organized by distinct events, with particular attention to duplicate results, previously reported developments, and different types of regulatory progress.
| Information Type | Representative Findings from This Test | How the Results Were Handled |
|---|---|---|
| Duplicate links across queries | The 291 results contained 247 unique URLs and 44 duplicate occurrences, based on exact URL matching. | Consolidated results by unique URL for subsequent processing. Reposts of the same content under different URLs still require further identification. |
| Multiple drugs covered in one announcement | Hengrui's SHR-A2102 and SHR-4849 were covered in the same announcement. | Retained information on both drugs and counted the announcement as one disclosure. |
| Previously reported developments recirculated | The original Mabwell webpage about 9MW2821 was published on April 23, 2026, and the relevant Sichuan Biokin announcement was published on October 12, 2026. | Excluded these developments from the list of new events within the seven-day monitoring window. |
| Related information that did not meet the event criteria | SAKIGAKE designation and Phase Ib/II clinical trial authorizations. | Classified separately and not counted as new Phase III clinical trial entries or marketing approvals. |
| Background information | Encyclopedia entries, search result pages, and historical research materials. | Used as supplementary background when needed, but not treated as evidence of new events. |
These figures reflect cross-query statistics and subsequent processing. They are not measures of the AnySearch search engine's internal deduplication rate or ranking performance.
This case demonstrates AnySearch's capabilities in public web search, cross-source information retrieval, and webpage content extraction for pharmaceutical industry monitoring. The retrieved information covered clinical trial registration records, company websites, and public announcements. The AI agent then used the model and processing rules to classify events, identify dates, consolidate duplicate information, and generate summaries while retaining source links. By saving these event records, subsequent tasks can compare new disclosures and changes in clinical trial phases and recruitment status, providing a basis for continuous monitoring.
Case note: These results were obtained through multiple search queries, Extract, and subsequent processing. Some announcements were also verified against archived copies of the original documents. Dates were taken from source content and were not returned as separate date fields directly by the search API.
Choose Free, Pro, or Enterprise Based on Your Needs
You can use any AnySearch plan to monitor news updates. Choose based on how often you search, how much content you need to retrieve, and what level of service you require. All three AnySearch plans support integration through APIs, MCP, and Skills.
| Plan | Pricing | Key Capabilities | Suitable Use Cases |
|---|---|---|---|
| Free | Free | General web search and search across 20+ available vertical domains, with source links and content summaries. Individual registered users receive 1,000 free requests per day. Students and developers who meet the verification requirements receive 2,000 free requests per day. | Daily news briefings, industry update monitoring, workflow development, and initial testing |
| Pro |
Limited-time offer: $3.00 / 1,000 requests Regular price: $5 / 1,000 requests |
Builds on the Free plan with expanded specialized data coverage, improved search quality and performance, and support for up to 20 QPS. | High-frequency searches, specialized industry monitoring, and analysis tasks that require full-text retrieval |
| Enterprise | Custom pricing | Builds on the Pro plan with expanded specialized data coverage, improved concurrency, and enhanced enterprise services. Supports dedicated quotas, custom rate limits, SLA commitments, and customized delivery. | Production environments involving multiple teams or applications, as well as those with specific service assurance or customization requirements |
Connect a Search Tool and Complete Your First Search Task
Choose an appropriate integration method based on the existing agent, business system, or automation tool:
| Integration Method | Suitable For | How to Get Started |
|---|---|---|
| MCP | Agents or clients that already support MCP | Follow the MCP Integration Guide to add the official hosted service. No local deployment is required, and anonymous access is supported. |
| REST API | Custom applications, business systems, or automated workflows | Follow the API Integration Guide to complete authentication and send search requests. |
| Skills | Agents that support Skills installation and execution | Refer to the Skills Integration Guide for instructions on installing and configuring Skills. |
After completing the integration, copy the following task into the agent to verify its news search and source retrieval capabilities:
Search for important news in the [XX industry] over the past seven days. Prioritize official company websites, regulatory authorities, and original reports. Organize the results by event, companies involved, disclosure date, and source links. Consolidate duplicate reports about the same event. List any information that cannot be verified separately and mark it clearly. If no matching results are found, state this accurately and do not add events that are not supported by sources.
After the first run, check the relevance of the results, dates, and supporting sources. Once the results meet expectations, configure scheduled execution, historical records, and notifications.
AnySearch handles search and content retrieval. The agent and the model handle event organization, duplicate detection, and summary generation. The workflow handles task scheduling, historical storage, and notifications.
Start Building Your Own News Monitoring Workflow
Choose an industry of interest, then use AnySearch Free to run your first search. If more frequent API calls, full-text retrieval, or enhanced specialized data coverage are needed, consider Pro. For enterprise production environments, dedicated quotas, SLA commitments, and customized services can also be evaluated.
After an enterprise trial application is reviewed and approved, applicants can receive 10,000 free requests for product testing, technical validation, and use case evaluation.
Try Free and Pro | Apply for an Enterprise Trial | View Integration Documentation
Top comments (0)